In its largest 2018 deal to date, Boston Scientific Corp., of Marlborough, Mass., agreed to acquire Bedford, Mass.-based Augmenix Inc., which has developed the SpaceOAR system to reduce the side effects that men may experience after receiving prostate cancer radiotherapy. The deal calls for an upfront cash payment of $500 million, plus up to $100 million for reaching sales-based milestones. Read More
Novocure has been working for a long time to establish the market for its device-based cancer treatment based on Tumor Treating Fields (TTF). Its Optune system was first approved by FDA in 2011 to treat glioblastoma (GBM) after chemotherapy, in the fall of 2015 it was kicked up to a first-line GBM treatment for adults in combination with chemotherapy temozolomide. Read More
PARIS – Luxembourg-based Steba Biotech SA is embarking on a series A round to raise $30 million to launch an already approved treatment vascular targeted focal photodynamic therapy (PDT) for early-stage prostate cancer in Europe. Read More
